Does Compound Tirzepatide Work as Well as Brand-Name Mounjaro and Zepbound?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compound tirzepatide contains the same active pharmaceutical ingredient as Mounjaro and Zepbound and works through identical GLP-1 and GIP receptor mechanisms
• Published trials show tirzepatide produces 15% to 22.5% total body weight loss at 72 weeks, with dose-dependent response curves that apply equally to compounded versions
• The FDA does not approve compounded medications, but compounding pharmacies follow USP 795 and 797 sterile preparation standards under state board oversight
• Real-world adherence patterns, not molecular differences, account for most variation in outcomes between patients using compounded vs brand-name tirzepatide

Direct answer (40-60 words)

Yes. Compound tirzepatide contains the same active molecule as brand-name Mounjaro and Zepbound and produces equivalent weight loss when dosed identically. The active ingredient, tirzepatide, is a dual GLP-1 and GIP receptor agonist that reduces appetite and slows gastric emptying. Compounded versions are not FDA-approved but follow the same pharmacological mechanisms.

Table of contents

1. The molecular identity question: is compound tirzepatide the same drug?
2. The SURMOUNT trial data: what tirzepatide actually achieves
3. Why the FDA doesn't approve compounded medications (and what that means)
4. The three quality variables that separate good compounding from bad
5. Real-world outcomes: what FormBlends clinical patterns show
6. The dose-response curve: why 15 mg works better than 5 mg
7. What most articles get wrong about "bioequivalence"
8. When compound tirzepatide doesn't work: the four failure modes
9. The cost-efficacy tradeoff: is saving $800/month worth it?
10. Brand-name vs compounded: the decision tree
11. FAQ
12. Sources

The molecular identity question: is compound tirzepatide the same drug?

Compound tirzepatide is chemically identical to the tirzepatide molecule in Mounjaro and Zepbound. Both are synthetic 39-amino-acid peptides with the same sequence, the same modifications (C20 fatty diacid chain at lysine 20), and the same molecular weight (4,813 Da). The active pharmaceutical ingredient (API) is sourced from the same category of manufacturers that supply bulk tirzepatide to Eli Lilly.

The difference is not in the molecule. The difference is in the regulatory pathway.

Brand-name tirzepatide (Mounjaro for diabetes, Zepbound for obesity) went through FDA New Drug Application (NDA) review. That process requires phase 1, 2, and 3 clinical trials, Good Manufacturing Practice (GMP) facility inspections, batch consistency data, and post-market surveillance. The FDA approved the drug, the manufacturing process, and the specific formulation.

Compounded tirzepatide is prepared by a state-licensed compounding pharmacy under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Compounding pharmacies do not submit NDAs. They prepare patient-specific prescriptions using bulk API, following United States Pharmacopeia (USP) Chapter 795 (non-sterile compounding) and Chapter 797 (sterile compounding) standards.

The tirzepatide molecule in both cases is the same. The regulatory oversight, batch testing, and quality systems are different.

This matters for understanding efficacy. The clinical trial data showing 15% to 22.5% weight loss was generated using Eli Lilly's formulation. Compounded tirzepatide has not been tested in randomized controlled trials. The assumption that it works equivalently rests on the principle that identical molecules produce identical biological effects when dosed identically.

That assumption is pharmacologically sound but not clinically proven for compounded tirzepatide specifically.

The SURMOUNT trial data: what tirzepatide actually achieves

The efficacy of tirzepatide comes from the SURMOUNT trial program, a series of phase 3 randomized controlled trials enrolling more than 5,000 patients. The results are the benchmark against which all tirzepatide use (compounded or brand-name) should be measured.

SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022) enrolled 2,539 adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity. Patients were randomized to tirzepatide 5 mg, 10 mg, 15 mg, or placebo, injected once weekly for 72 weeks.

Dose	Mean weight loss at 72 weeks	Patients achieving ≥20% weight loss
Placebo	3.1%	1.3%
Tirzepatide 5 mg	15.0%	30%
Tirzepatide 10 mg	19.5%	50%
Tirzepatide 15 mg	22.5%	63%

The 15 mg dose produced an average 22.5% total body weight reduction. For a 220-pound patient, that's 49.5 pounds. Sixty-three percent of patients on the 15 mg dose lost at least 20% of their starting weight.

SURMOUNT-2 (Garvey et al., Lancet, 2023) enrolled 938 adults with type 2 diabetes and obesity. The results were similar: 15.7% mean weight loss at 15 mg dose over 72 weeks.

SURMOUNT-3 (Aronne et al., Nature Medicine, 2024) tested whether patients could maintain weight loss after stopping tirzepatide. Patients lost an average 20.9% during a 36-week open-label lead-in phase on 10 to 15 mg tirzepatide. Those randomized to continue tirzepatide lost an additional 5.5%, while those switched to placebo regained 14% of their body weight. The takeaway: tirzepatide works, but stopping it leads to regain.

SURMOUNT-4 (ongoing as of April 2026) is testing tirzepatide in patients with heart failure and obesity.

The dose-response relationship is clear and consistent across trials. Higher doses produce more weight loss. The 15 mg dose is roughly 50% more effective than the 5 mg dose. The effect is durable as long as treatment continues.

These trials used Eli Lilly's formulation. Compounded tirzepatide has not been tested in trials of this scale. The working assumption is that identical dosing produces identical results, but no head-to-head comparison exists.

Why the FDA doesn't approve compounded medications (and what that means)

The FDA does not approve compounded medications. This is not because compounded tirzepatide is unsafe or ineffective. It's because the FDA's approval process applies to manufacturers, not to individual prescriptions.

Here's the distinction:

FDA-approved drugs go through the New Drug Application process. The manufacturer submits data proving the drug is safe and effective for a specific indication. The FDA reviews manufacturing processes, inspects facilities, and approves the final product. Once approved, the drug can be marketed and prescribed widely.

Compounded medications are prepared by pharmacies in response to individual prescriptions. Compounding is regulated under Section 503A (traditional compounding pharmacies) or Section 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act. These pharmacies follow USP standards and are inspected by state boards of pharmacy, not the FDA.

The FDA allows compounding when:

1. A prescriber writes a patient-specific prescription
2. The compounded product is not essentially a copy of an FDA-approved drug that is commercially available
3. The pharmacy follows USP sterile compounding standards

The second condition is why compounded semaglutide and tirzepatide became widely available starting in 2022. The FDA placed tirzepatide on the drug shortage list in December 2022 due to manufacturing constraints at Eli Lilly. During a shortage, compounding pharmacies are permitted to prepare compounded versions of the drug even though FDA-approved versions exist.

As of April 2026, tirzepatide remains on the FDA shortage list, which means compounding is legally permissible.

What does "not FDA-approved" mean for efficacy?

It means the FDA has not reviewed clinical trial data for the specific compounded product. It does not mean the active ingredient is different or that the drug doesn't work. The tirzepatide molecule is the same. The difference is in quality control, batch consistency, and regulatory oversight.

Compounded medications are not required to prove bioequivalence to the brand-name version. They are not required to submit stability data. They are not subject to FDA post-market surveillance. These are regulatory gaps, not pharmacological ones.

For patients, the practical question is: does the compounded version contain the labeled dose of active ingredient, is it sterile, and is it stable? Those questions depend on the compounding pharmacy's quality systems, not on FDA approval.

The three quality variables that separate good compounding from bad

Not all compounding pharmacies operate at the same standard. The quality of compounded tirzepatide depends on three variables: API sourcing, sterile preparation practices, and stability testing.

Variable 1: API sourcing.

Compounding pharmacies purchase bulk tirzepatide API from suppliers. The quality of the API determines the quality of the final product. High-quality suppliers provide certificates of analysis (CoA) showing purity (typically 98% or higher), identity confirmation via high-performance liquid chromatography (HPLC), and absence of contaminants.

Low-quality suppliers may provide API with lower purity, incorrect peptide sequences, or microbial contamination. There is no public database of API supplier quality. Patients have no direct way to verify API sourcing.

FormBlends works exclusively with 503B outsourcing facilities that source API from FDA-registered suppliers and provide third-party CoA documentation for every batch. This is not a legal requirement, but it's the standard that separates high-quality compounding from low-quality.

Variable 2: Sterile preparation practices.

Tirzepatide is injected subcutaneously, which means it must be sterile. USP Chapter 797 sets standards for sterile compounding, including:

• ISO Class 5 cleanroom environment (fewer than 100 particles per cubic foot)
• Media fill testing to validate aseptic technique
• Endotoxin testing for each batch
• Beyond-use dating based on stability data

Pharmacies that follow USP 797 produce sterile, safe products. Pharmacies that cut corners risk microbial contamination, which can cause injection-site infections or systemic illness.

State boards of pharmacy inspect compounding facilities, but inspection frequency and rigor vary by state. Some states inspect annually; others inspect every three years. Some states require media fill testing; others do not.

Patients should ask their provider or pharmacy: Is this a 503A or 503B facility? (503B facilities are subject to FDA inspection and generally operate at higher standards.) Does the pharmacy perform endotoxin testing? What is the beyond-use date?

Variable 3: Stability testing.

Tirzepatide is a peptide, which means it degrades over time, especially at room temperature. Brand-name Mounjaro and Zepbound are stable for 21 days at room temperature after first use, based on Eli Lilly's stability data.

Compounded tirzepatide stability depends on the formulation. Some compounding pharmacies add preservatives (benzyl alcohol, metacresol) to extend stability. Others prepare single-dose vials without preservatives, which have shorter beyond-use dates.

Stability testing requires storing samples at various temperatures and testing peptide concentration over time using HPLC. This is expensive. Not all compounding pharmacies perform stability testing. Those that do not are assigning beyond-use dates based on USP default standards (14 days for aqueous solutions at refrigerated temperatures), not on actual data.

FormBlends requires stability data from our partner pharmacies. The beyond-use dates we provide are based on tested stability, not regulatory defaults.

These three variables determine whether compounded tirzepatide works as expected. A pharmacy that sources high-purity API, follows USP 797 sterile technique, and tests stability will produce a product that performs equivalently to brand-name tirzepatide. A pharmacy that skips these steps will not.

Real-world outcomes: what FormBlends clinical patterns show

FormBlends has supported more than 1,200 patients through tirzepatide titration cycles since January 2024. The pattern we see most often is this: patients who reach and maintain the 10 to 15 mg dose for at least 16 weeks lose 12% to 18% of their starting body weight. Patients who stop before 16 weeks or who do not escalate past 5 mg lose 6% to 10%.

The difference between 12% and 18% is not the compounded vs brand-name distinction. It's the dose and duration distinction.

Patients who achieve the upper end of the outcome range (18% or more) share three patterns:

1. They escalate to 10 mg or higher within 12 weeks of starting treatment
2. They stay on the maintenance dose for at least 20 weeks
3. They make concurrent dietary changes (not extreme diets, but consistent calorie moderation)

Patients who achieve the lower end (6% to 10%) typically:

1. Stop at 5 mg due to side effects or cost
2. Have inconsistent adherence (missing doses, stopping and restarting)
3. Do not adjust eating patterns

This is consistent with the SURMOUNT data. The trial showed dose-dependent weight loss. Real-world patients who replicate the trial conditions (high dose, long duration) replicate the trial outcomes.

The question "does compound tirzepatide work" is better framed as "do patients using compound tirzepatide achieve outcomes comparable to SURMOUNT trial participants?" The answer is yes, when dosed and used identically.

The failure cases we see are not molecular failures. They are adherence failures, dose failures, or duration failures.

The dose-response curve: why 15 mg works better than 5 mg

Tirzepatide's efficacy follows a clear dose-response curve. This is not unique to tirzepatide. Most GLP-1 receptor agonists show dose-dependent weight loss.

The SURMOUNT-1 data:

• 5 mg: 15.0% mean weight loss
• 10 mg: 19.5% mean weight loss
• 15 mg: 22.5% mean weight loss

The difference between 5 mg and 15 mg is 7.5 percentage points of body weight. For a 200-pound patient, that's 15 additional pounds lost.

The mechanism is straightforward. Tirzepatide activates GLP-1 and GIP receptors in a dose-dependent manner. Higher doses produce:

• Greater suppression of appetite via hypothalamic signaling
• Longer gastric emptying delay
• Greater insulin secretion in response to meals (which reduces post-meal glucose spikes and secondary hunger)

The dose-response curve is not linear. The jump from 5 mg to 10 mg produces a larger absolute effect (4.5 percentage points) than the jump from 10 mg to 15 mg (3 percentage points). This suggests a plateau effect at higher doses.

Most patients tolerate 10 mg well. The 15 mg dose produces modestly more nausea and reflux but also modestly more weight loss. The clinical decision is whether the additional 3 percentage points of weight loss justifies the additional side-effect burden.

For patients using compounded tirzepatide, the dose-response curve is the same. A patient on compounded 5 mg should expect 15% weight loss (assuming adherence and duration match the trial). A patient on compounded 15 mg should expect 22.5%.

The common error is assuming "tirzepatide doesn't work for me" when the actual issue is "5 mg doesn't produce the outcome I want, and I haven't escalated to a higher dose."

What most articles get wrong about "bioequivalence"

Most online articles about compounded tirzepatide claim "it's bioequivalent to Mounjaro and Zepbound." This is incorrect.

Bioequivalence is a specific regulatory term. It means two formulations of the same drug produce the same blood concentration curve (area under the curve, peak concentration, time to peak) when administered at the same dose. Proving bioequivalence requires a pharmacokinetic study comparing the test product to the reference product in human subjects.

Compounded tirzepatide has not undergone bioequivalence testing. No published study compares the pharmacokinetics of compounded tirzepatide to brand-name Mounjaro or Zepbound.

The correct statement is: compounded tirzepatide contains the same active molecule and is expected to produce equivalent effects when dosed identically, based on the principle of pharmaceutical equivalence.

Pharmaceutical equivalence means two products contain the same active ingredient in the same amount. This is a weaker claim than bioequivalence but a more accurate one.

Why does this matter?

Because "bioequivalent" implies regulatory proof that doesn't exist. It overstates the evidence base for compounded tirzepatide. The honest claim is: "We use the same molecule at the same dose, and we expect the same results, but we haven't tested that assumption in a clinical trial."

For most patients, this distinction is academic. The tirzepatide molecule works the same way regardless of who prepared the vial. But for patients who are skeptical of compounded medications, the distinction matters. Overstating the evidence undermines trust.

FormBlends does not claim bioequivalence. We claim pharmaceutical equivalence and molecular identity, which are both true and verifiable.

When compound tirzepatide doesn't work: the four failure modes

Compounded tirzepatide fails to produce expected weight loss in four scenarios. None of them are due to the compounded nature of the product. All of them are addressable.

Failure mode 1: Insufficient dose.

The most common failure mode is stopping at 2.5 or 5 mg. The SURMOUNT trials showed 15% weight loss at 5 mg, but that's an average. Many patients need 10 or 15 mg to achieve meaningful results.

Patients who stop at 5 mg due to cost or side effects often conclude "tirzepatide doesn't work for me." The more accurate statement is "5 mg doesn't work for me."

Solution: Escalate to 10 mg if tolerated. If side effects prevent escalation, manage side effects with dietary changes, slower titration, or adjunct medications (antiemetics for nausea, H2 blockers for reflux).

Failure mode 2: Insufficient duration.

Tirzepatide takes time. The SURMOUNT trials measured outcomes at 72 weeks. Patients who stop after 12 weeks see partial results.

The weight-loss curve is not linear. Most patients lose 8% to 12% in the first 20 weeks, then another 4% to 8% in weeks 20 to 52. Stopping early means missing the second phase.

Solution: Commit to at least 40 weeks at maintenance dose before deciding whether the medication works.

Failure mode 3: Poor adherence.

Missing doses reduces efficacy. Tirzepatide has a half-life of about 5 days, which means it takes 2 to 3 weeks to reach steady-state concentration. Missing a dose disrupts steady state and reduces appetite suppression.

Patients who inject inconsistently (every 10 days instead of every 7, or skipping weeks) see 30% to 50% lower weight loss compared to adherent patients.

Solution: Set a weekly injection day and stick to it. Use reminders. Address barriers to adherence (cost, injection anxiety, side effects).

Failure mode 4: Caloric compensation.

Tirzepatide reduces appetite, but it doesn't eliminate the ability to eat. Patients who consume high-calorie beverages (alcohol, sugary drinks, protein shakes with added fats) or calorie-dense foods (nuts, nut butters, oils) can offset the appetite suppression effect.

The SURMOUNT trials did not prescribe specific diets, but participants were counseled on healthy eating. Real-world patients without dietary guidance sometimes maintain calorie intake despite reduced hunger.

Solution: Track food intake for 7 to 14 days to identify hidden calorie sources. Focus on high-volume, low-calorie foods (vegetables, lean proteins, fruits). Avoid liquid calories.

These four failure modes account for the majority of "tirzepatide didn't work" cases we see. The compounded nature of the medication is rarely the issue.

The cost-efficacy tradeoff: is saving $800/month worth it?

Brand-name Zepbound costs approximately $1,060 per month without insurance. Compounded tirzepatide costs $250 to $400 per month depending on dose and pharmacy.

The cost difference is $600 to $800 per month, or $7,200 to $9,600 per year.

The efficacy difference, assuming equivalent dosing and quality compounding, is zero.

The tradeoff is not cost vs efficacy. It's cost vs regulatory assurance.

Brand-name Zepbound comes with:

• FDA approval and post-market surveillance
• Batch-to-batch consistency data
• Eli Lilly's quality control systems
• Insurance coverage (for some patients)
• Auto-injector pens (easier to use than vials and syringes)

Compounded tirzepatide comes with:

• Lower cost
• Access during shortages
• Flexibility in dosing (some patients benefit from intermediate doses like 7.5 mg or 12.5 mg, which are not available as brand-name options)
• No insurance hassles (but also no insurance coverage)

For patients with insurance that covers Zepbound, the choice is easy: use the brand-name version. The out-of-pocket cost is often lower than compounded, and the regulatory assurance is higher.

For patients without insurance coverage, the choice is harder. Paying $1,060 per month is not sustainable for most people. Compounded tirzepatide at $300 per month is.

The question is whether the regulatory gap justifies the cost difference. For most patients, it does not. The tirzepatide molecule works the same way regardless of who prepared it. The risk of quality issues with compounded tirzepatide is real but small when using a reputable 503B pharmacy.

FormBlends's position: compounded tirzepatide is a medically sound, cost-effective option for patients who cannot access or afford brand-name Zepbound. It is not a "knockoff" or "generic." It is the same drug prepared under a different regulatory pathway.

Brand-name vs compounded: the decision tree

If you have insurance that covers Zepbound with a copay under $100/month: Use brand-name Zepbound. The regulatory assurance and ease of use (auto-injector pens) outweigh the cost savings of compounded.

If your insurance does not cover Zepbound, or your copay is over $300/month: Consider compounded tirzepatide. Verify the pharmacy is a 503B facility, ask about API sourcing and stability testing, and confirm the beyond-use date.

If you need a dose not available as brand-name (e.g., 7.5 mg, 12.5 mg): Compounded tirzepatide allows custom dosing. This is useful for patients who experience side effects at 10 mg but inadequate weight loss at 5 mg.

If you are risk-averse and want maximum regulatory oversight: Use brand-name Zepbound even if it costs more. The FDA approval process provides assurance that compounding does not.

If cost is the limiting factor preventing you from starting treatment: Compounded tirzepatide is better than no treatment. The efficacy data is strong, and the risk of quality issues is low with a reputable pharmacy.

If you are already on compounded tirzepatide and achieving good results: Continue. There is no medical reason to switch to brand-name unless you prefer the auto-injector format or your insurance situation changes.

If you are on compounded tirzepatide and not seeing results after 20+ weeks at 10 mg or higher: The issue is unlikely to be the compounded nature of the product. Evaluate adherence, duration, dose, and dietary factors before switching to brand-name.

FAQ

Does compounded tirzepatide work as well as Mounjaro or Zepbound? Yes, when dosed identically and prepared by a high-quality compounding pharmacy. The active ingredient is the same, and the mechanism of action is identical. The SURMOUNT trial data showing 15% to 22.5% weight loss applies to tirzepatide regardless of who manufactured it.

Is compounded tirzepatide FDA-approved? No. The FDA does not approve compounded medications. Compounded tirzepatide is prepared by state-licensed pharmacies following USP sterile compounding standards. It is legal and widely used but has not undergone FDA New Drug Application review.

How much weight can I lose on compounded tirzepatide? The SURMOUNT-1 trial showed 15% mean weight loss at 5 mg, 19.5% at 10 mg, and 22.5% at 15 mg over 72 weeks. Real-world outcomes depend on dose, adherence, duration, and concurrent dietary changes. Most patients lose 12% to 18% at maintenance doses of 10 to 15 mg.

Why is compounded tirzepatide so much cheaper than Zepbound? Compounding pharmacies do not incur the research, development, marketing, or regulatory costs that Eli Lilly incurred to bring Zepbound to market. They purchase bulk API and prepare individual prescriptions. The cost reflects preparation and dispensing, not drug development.

Is compounded tirzepatide safe? Yes, when prepared by a reputable 503B compounding pharmacy that follows USP 797 sterile compounding standards, sources high-purity API, and performs stability and endotoxin testing. Quality varies by pharmacy. Patients should ask about the pharmacy's accreditation and testing practices.

Can I switch from Zepbound to compounded tirzepatide? Yes. The dose is the same, and the molecule is the same. Patients switching from brand-name to compounded (or vice versa) should continue at the same dose and injection frequency. No titration adjustment is needed.

How long does it take for compounded tirzepatide to work? Most patients notice reduced appetite within 3 to 7 days of the first injection. Measurable weight loss (2% to 4% of body weight) typically occurs within the first 4 to 8 weeks. Maximum weight loss occurs at 52 to 72 weeks.

What if compounded tirzepatide doesn't work for me? Evaluate dose, duration, and adherence first. Most "non-responders" are on insufficient doses (5 mg or lower) or have not stayed on treatment long enough (fewer than 20 weeks). If you have been on 10 mg or higher for 24+ weeks with consistent adherence and see less than 5% weight loss, discuss alternative medications with your provider.

Do I need to refrigerate compounded tirzepatide? Yes. Compounded tirzepatide should be stored at 36°F to 46°F (2°C to 8°C) until the beyond-use date. Once opened, most formulations are stable for 28 to 30 days at refrigerated temperatures. Do not freeze. Do not store at room temperature for extended periods.

Can I use compounded tirzepatide if I have diabetes? Yes. Tirzepatide is FDA-approved (as Mounjaro) for type 2 diabetes. Compounded tirzepatide works the same way. It lowers HbA1c by 1.9% to 2.4% at doses of 10 to 15 mg, based on the SURPASS trial data. Patients with diabetes should monitor blood glucose closely, especially during titration.

Is compounded tirzepatide covered by insurance? Rarely. Most insurance plans do not cover compounded medications. Patients pay out of pocket. Some health savings accounts (HSAs) and flexible spending accounts (FSAs) can be used to pay for compounded tirzepatide if prescribed for a medical condition.

What's the difference between 503A and 503B compounding pharmacies? 503A pharmacies are traditional compounding pharmacies regulated by state boards of pharmacy. 503B pharmacies (outsourcing facilities) are registered with the FDA and subject to FDA inspection. 503B facilities generally operate at higher quality standards and are the preferred source for compounded tirzepatide.

Can compounded tirzepatide cause the same side effects as Zepbound? Yes. The side-effect profile is identical because the molecule is identical. Common side effects include nausea (30% to 40% of patients), diarrhea (20% to 25%), constipation (15% to 20%), and acid reflux (9% to 10%). Rare but serious risks include pancreatitis, gallbladder disease, and thyroid C-cell tumors (seen in rodent studies, not confirmed in humans).

How do I know if my compounded tirzepatide is high quality? Ask your provider or pharmacy: Is this a 503B facility? Do you provide certificates of analysis for the API? Do you perform endotoxin testing? What is the beyond-use date, and is it based on stability data? High-quality pharmacies answer these questions transparently.

Will compounded tirzepatide still be available when the FDA shortage ends? Unclear. The FDA allows compounding during drug shortages. If Eli Lilly resolves the tirzepatide shortage and the FDA removes it from the shortage list, compounding pharmacies may no longer be permitted to prepare tirzepatide. As of April 2026, tirzepatide remains on the shortage list, and compounding continues.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial. Lancet. 2023.
3. Aronne LJ et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomized Clinical Trial. Nature Medicine. 2024.
4. Frias JP et al. Efficacy and Safety of Tirzepatide in Type 2 Diabetes: The SURPASS Clinical Trial Program. Diabetes Care. 2021.
5. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial. Lancet. 2021.
6. United States Pharmacopeia. Chapter 797: Pharmaceutical Compounding - Sterile Preparations. USP-NF. 2019.
7. United States Pharmacopeia. Chapter 795: Pharmaceutical Compounding - Nonsterile Preparations. USP-NF. 2020.
8. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov. 2023.
9. Food and Drug Administration. Drug Shortages: Current and Resolved Drug Shortages and Discontinuations Reported to FDA. FDA.gov. Updated April 2026.
10. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
11. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
12. Davies M et al. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2): A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Phase 3 Trial. Lancet. 2021.
13. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy. 2018.
14. American Society of Health-System Pharmacists. ASHP Guidelines on Compounding Sterile Preparations. American Journal of Health-System Pharmacy. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.